Naringenin

Grapefruit juice containing naringenin and furanocoumarins is well-documented to inhibit intestinal CYP3A4, increasing bioavailability of many medications by >70% for felodipine, nisoldipine, and saquinavir (PMID 9565737). Naringenin also inhibits P-glycoprotein transport (PMID 17542018). However, furanocoumarins rather than naringenin may be the primary CYP3A4 inhibitors (PMID 8809221). Multiple human pharmacokinetic studies confirm significant drug interactions.

Multiple preclinical studies consistently show naringenin reduces plasma and hepatic triglycerides. In rats, dietary naringenin decreased plasma triglycerides and adiposity via PPARalpha activation (PMID 20567977). In vitro studies demonstrate naringenin inhibits hepatocyte apoB-lipoprotein secretion through MTP inhibition (PMID 12564931) and induces a fasted-like hepatic metabolic state via PPARalpha/PPARgamma activation and LXRalpha inhibition (PMID 20811644). No direct human trials for lipid outcomes.

In a rat model, oral naringenin (20-50 mg/kg/day for 4 weeks) prevented dimethylnitrosamine-induced liver damage, reducing serum liver enzymes, oxidative stress, collagen deposition, and hepatic stellate cell activation (PMID 14709902). In vitro studies show naringenin modulates hepatic lipid metabolism via PPARalpha activation (PMID 20811644), suggesting potential hepatoprotective benefit. No human trials exist.

In L6 muscle cells, naringenin (75 microM for 2 hours) stimulated glucose uptake by 192.8%, comparable to insulin, via AMPK activation. siRNA knockdown of AMPK abolished the effect, confirming the mechanism (PMID 20558145). No human studies have evaluated naringenin's effect on glucose metabolism.

In a mouse model of DSS-induced colitis, naringenin significantly reduced disease severity and inflammatory markers via suppression of TLR4/NF-kappaB signaling. In vitro studies confirmed naringenin blocked inflammatory responses in macrophage and intestinal epithelial cell lines (PMID 23506745). No human data available.

In rats with spinal nerve ligation-induced neuropathic pain, intrathecal naringenin dose-dependently attenuated mechanical allodynia and thermal hyperalgesia by reducing spinal glial cell activation and inflammatory mediators (PMID 24944810). No human studies have evaluated analgesic effects.

In a crossover trial of 8 postmenopausal women receiving micronized estradiol, grapefruit juice significantly increased peak estrone concentrations by inhibiting oxidative estrogen degradation (PMID 7715468). This suggests grapefruit flavonoids including naringenin may alter hormone levels, relevant to both drug interactions and estrogen-dependent conditions.

A review of literature (PMID 25483717) summarizes consistent preclinical evidence that naringenin reduces LDL and triglycerides, increases HDL, suppresses macrophage inflammation, and inhibits foam cell formation. In mice, naringin reduced atherosclerotic plaque by 41% over 18 weeks (PMID 21684135). One human RCT showed reduced arterial stiffness (PMID 26016866), supporting vascular benefit.

A 6-month randomized, controlled, crossover trial in 48 postmenopausal women found that daily grapefruit juice consumption (containing ~210 mg naringenin glycosides) significantly reduced carotid-femoral pulse wave velocity, indicating decreased arterial stiffness (PMID 26016866). Preclinical studies in hypercholesterolemic mice show naringin reduces atherosclerotic plaque progression by 41% (PMID 21684135).

In 10 healthy volunteers, 1L of pink grapefruit juice produced peak QTc prolongation of 12.5 +/- 4.2 ms at 5 hours via HERG channel blockade; naringenin was the most potent flavonoid inhibitor among 10 tested (PMID 15710766). In 32 participants including cardiomyopathy patients, grapefruit juice significantly increased QT variability indices comparable to sotalol (PMID 18433709). This represents a cardiac safety concern, particularly for patients with structural heart disease.

Naringenin and other citrus flavonoids inhibited human breast cancer cell proliferation in vitro, with IC50 values of 5.9-140 microg/mL. Combined flavonoids showed synergistic effects. In rats, citrus juice delayed mammary tumorigenesis after carcinogen exposure (PMID 8875554). A separate review noted anti-mammary cancer potential of citrus flavonoids (PMID 9781306). All evidence is preclinical.